Currently Viewing:
American Society of Clinical Oncology Annual Meeting
Currently Reading
Persephone Trial: Cutting Trastuzumab Duration by Half Safer, Efficacious in HER2-Positive Breast Cancer
May 29, 2018
Despite USPSTF Recommendations, Lung Screening Rates Low Among Heavy Smokers
May 31, 2018
Nelarabine With Chemotherapy Boosted Outcomes in Pediatric and YA Patients With T-Cell Cancers
June 01, 2018
Dr Leonard B. Saltz on Deciding When a Patient Should Receive NGS Testing
June 02, 2018
Promising Early Phase Results With bb2121 CAR T Treatment in Relapsed Refractory Multiple Myeloma
June 02, 2018
Dr Peter Paul Yu Discusses the Impact of Health Information Technology in Oncology
June 02, 2018
Identifying Rational Immunotherapy Combinations for Glioblastoma: A Progress Report
June 02, 2018
Dr James Lin Chen Outlines Information Needs in Era of Precision Medicine
June 02, 2018
Ellen Miller Sonet Highlights Financial Burdens of Patients With Cancer
June 02, 2018
Utilization Management in Oncology: Current Strategies and a Path Forward
June 02, 2018
Immune Checkpoint Inhibitors Improve Outcomes in Mismatch Repair Deficient CRC, but Can Induce irAEs
June 02, 2018
ZUMA-1: Response to Axi-cel at Three Months Prognostic for Remission in B-cell Lymphoma
June 03, 2018
Cetuximab With Chemoradiation Worse Than Chemoradiation Alone in Older Patients With HNSCC
June 03, 2018
Dr Michael Thompson: The Role of Precision Medicine in the Community Setting
June 03, 2018
Dr Victoria Villaflor Outlines Challenges With Pursuing Precision Medicine
June 03, 2018
Clinical Trials: Sharing the Road With Real-World Evidence
June 04, 2018
Phase 3 TAILORx Results Confirm Chemotherapy Unnecessary in 70% of Women With Early-Stage Breast Cancer
June 04, 2018
KEYNOTE-042 Confirms First-Line Pembrolizumab Superior to Chemotherapy in PD-L1–Low Advanced NSCLC
June 04, 2018
Cemiplimab, in GOG 3016, Looks to Break New Ground for Immunotherapy in Cervical Cancer
June 04, 2018
Nearly Half of Patients With Metastatic CSCC Respond to Cemiplimab, on Fast Track at FDA
June 04, 2018
Opdivo Plus Chemo Boosts Progression-Free Survival 26% Over Chemo Alone in Late-Stage NSCLC
June 04, 2018
Managing Cancer-Related Pain in the Era of the Opioid Crisis
June 06, 2018
Discussing the Cost Burden of Cancer With Patients
June 06, 2018
Study Underscores Value of PROs in Improving Lung Cancer Survival
June 07, 2018

Dr Sara M. Tolaney Discusses the Role of Adjuvant Therapy in HER2-Positive Breast Cancer

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, outlines the role of adjuvant therapy in treating patients with HER2-positive breast cancer, as well as the absence of biomarkers in this patient population.


Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, outlines the role of adjuvant therapy in treating patients with HER2-positive breast cancer, as well as the absence of biomarkers in this patient population.

Transcript

What role does adjuvant treatment play in the treatment of HER2-positive breast cancer?

I think the landscape in the adjuvant setting has also changed. Typically, the way we had previously approached patients with HER2-positive disease had been to either give a regimen called AC chemotherapy, followed by a taxane and Herceptin, or we would give a non-anthracycline-based therapy, which we call TCH, so using a docetaxel with carboplatin and trastuzumab. But, now we’ve seen introduction of a few new HER2 agents into the early-stage setting, one being pertuzumab.

So, there’s the APHINITY data that came out last year that showed that when you add pertuzumab to standard chemotherapy with trastuzumab, it resulted in an improvement in disease-free survival. That being said, that improvement was pretty small and seemed to be greater in patients who had higher risk disease. So, patients, for example, who had either node-positive disease or hormone-receptor-negative disease. So, at this point in time, we are, generally, incorporating pertuzumab into patients who have higher risk for HER2- positive disease.

One other agent we’re also including is neratinib, and this is a potent tyrosine kinase inhibitor against HER1, HER2, and HER4. This agent was studied in the exteNET trial, which looked at patients who had completed a year of trastuzumab based therapy, and then they got randomized to get a year of neratinib or nothing. They found that getting a year of neratinib, after completion of your year of trastuzumab, did provide additional benefit, but the benefit was really seen in the hormone-receptor-positive patients.

So, we do think about using neratinib in someone who had a particularly high-risk ER-positive tumor. I will said, that being said, the patients that were enrolled onto exteNET were all pertuzumab naïve, and now that we’re starting to integrate pertuzumab into adjuvant therapy, we really don’t have data about what the benefits are for using neratinib in someone who’s had prior pertuzumab.

Are there any identified biomarkers that guide a treatment approach for these patients?

Not at this time. I wish, but there aren’t any defined biomarkers that can help us predict which patients are likely to benefit from which treatment. I think where it would be particularly beneficial to us would be in trying to decide which patients are going to benefit from pertuzumab because the absolute benefit was small, then, I think there’s likely to be greater benefit in patients who may have certain biological predisposition to getting benefit from pertuzumab. So, there is ongoing work trying to look at biomarker predictors from the affinity trial that we’re waiting.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!